{"doi":"10.3390/pharmaceutics13030331","title":"Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network","abstract":"<jats:p>The noradrenaline and dopamine reuptake inhibitor bupropion is metabolized by CYP2B6 and recommended by the FDA as the only sensitive substrate for clinical CYP2B6 drug–drug interaction (DDI) studies. The aim of this study was to build a whole-body physiologically based pharmacokinetic (PBPK) model of bupropion including its DDI-relevant metabolites, and to qualify the model using clinical drug–gene interaction (DGI) and DDI data. The model was built in PK-Sim® applying clinical data of 67 studies. It incorporates CYP2B6-mediated hydroxylation of bupropion, metabolism via CYP2C19 and 11β-HSD, as well as binding to pharmacological targets. The impact of CYP2B6 polymorphisms is described for normal, poor, intermediate, and rapid metabolizers, with various allele combinations of the genetic variants CYP2B6*1, *4, *5 and *6. DDI model performance was evaluated by prediction of clinical studies with rifampicin (CYP2B6 and CYP2C19 inducer), fluvoxamine (CYP2C19 inhibitor) and voriconazole (CYP2B6 and CYP2C19 inhibitor). Model performance quantification showed 20/20 DGI ratios of hydroxybupropion to bupropion AUC ratios (DGI AUCHBup/Bup ratios), 12/13 DDI AUCHBup/Bup ratios, and 7/7 DDGI AUCHBup/Bup ratios within 2-fold of observed values. The developed model is freely available in the Open Systems Pharmacology model repository.</jats:p>","journal":"Pharmaceutics","year":2021,"id":678035,"datarank":0.4493598410330987,"base_score":2.995732273553991,"endowment":2.995732273553991,"self_citation_contribution":0.4493598410330987,"citation_network_contribution":0.0,"self_endowment_contribution":0.4493598410330987,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":19,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1771576,"name":"Laura Maria Fuhr","orcid":null,"position":1,"is_corresponding":false},{"id":1771578,"name":"Nina Hanke","orcid":"0000-0001-6166-8838","position":2,"is_corresponding":false},{"id":1771580,"name":"Dominik Selzer","orcid":null,"position":3,"is_corresponding":false},{"id":1712358,"name":"Thorsten Lehr","orcid":"0000-0002-8372-1465","position":4,"is_corresponding":false},{"id":1771574,"name":"Fatima Zahra Marok","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network","abstract":"<jats:p>The noradrenaline and dopamine reuptake inhibitor bupropion is metabolized by CYP2B6 and recommended by the FDA as the only sensitive substrate for clinical CYP2B6 drug–drug interaction (DDI) studies. The aim of this study was to build a whole-body physiologically based pharmacokinetic (PBPK) model of bupropion including its DDI-relevant metabolites, and to qualify the model using clinical drug–gene interaction (DGI) and DDI data. The model was built in PK-Sim® applying clinical data of 67 studies. It incorporates CYP2B6-mediated hydroxylation of bupropion, metabolism via CYP2C19 and 11β-HSD, as well as binding to pharmacological targets. The impact of CYP2B6 polymorphisms is described for normal, poor, intermediate, and rapid metabolizers, with various allele combinations of the genetic variants CYP2B6*1, *4, *5 and *6. DDI model performance was evaluated by prediction of clinical studies with rifampicin (CYP2B6 and CYP2C19 inducer), fluvoxamine (CYP2C19 inhibitor) and voriconazole (CYP2B6 and CYP2C19 inhibitor). Model performance quantification showed 20/20 DGI ratios of hydroxybupropion to bupropion AUC ratios (DGI AUCHBup/Bup ratios), 12/13 DDI AUCHBup/Bup ratios, and 7/7 DDGI AUCHBup/Bup ratios within 2-fold of observed values. The developed model is freely available in the Open Systems Pharmacology model repository.</jats:p>","is_dataset_classified":null,"base_score":2.995732273553991,"endowment":2.995732273553991,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"33806634","pmcid":"PMC8001859","openalex_id":"https://openalex.org/W3133873564","authors":[],"funders":[{"funder_name":"Bundesministerium für Bildung und Forschung","grant_id":"031L0161C","title":null},{"funder_name":"Deutsche Forschungsgemeinschaft","grant_id":"-","title":null},{"funder_name":"Deutsche Forschungsgemeinschaft","grant_id":"","title":null}],"total_grants":3,"fwci":2.1885,"citation_percentile":0.86309297,"influential_citations":0,"citation_trend":[{"year":2021,"count":3},{"year":2022,"count":3},{"year":2023,"count":2},{"year":2024,"count":5},{"year":2025,"count":4},{"year":2026,"count":2}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/1999-4923/13/3/331/pdf","host_type":"journal"},{"url":"https://www.mdpi.com/1999-4923/13/3/331/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/pharmaceutics13030331","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/33806634","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8001859","host_type":"repository"},{"url":"https://doaj.org/article/b3bcfa10bc1840e9977b6dfb74690fd3","host_type":"repository"},{"url":"https://dx.doi.org/10.3390/pharmaceutics13030331","host_type":"repository"},{"url":"http://dx.doi.org/10.22028/D291-33673","host_type":"repository"},{"url":"https://doi.org/10.22028/d291-33673","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC8001859","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC8001859?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Pharmacogenetics and Drug Metabolism","Analytical Methods in Pharmaceuticals","Schizophrenia research and treatment"],"mesh_terms":[],"keywords":["CYP2B6","Bupropion","Pharmacology","CYP2C19","Physiologically based pharmacokinetic modelling","Pharmacokinetics","CYP3A4","Drug","Drug metabolism","CYP2D6","Fluvoxamine","Drug interaction","Cytochrome P450","Chemistry","Medicine","Internal medicine","Metabolism","Fluoxetine","Smoking cessation","Physiologically Based Pharmacokinetic Modeling","Hydroxybupropion","Cytochrome P450 2B6 (Cyp2b6)","Drug-Drug-Interactions (Ddis)","Drug-Gene-Interactions (Dgis)"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"No poverty"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"doi"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-17T04:51:56.135879Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}